Zynex, Inc.
8022 Southpark Circle
Suite 100
Littleton,
CO 80120
United States - Map
Phone: 303-703-4906
Fax: 800-495-6695
Web Site: http://www.zynexmed.com
| Zynex, Inc. engineers, manufactures, markets, and sells medical devices for the electrotherapy, and stroke and spinal cord injury rehabilitation markets primarily in the United States. The company primarily offers electrotherapy products for pain relief and pain management; and NeuroMove for stroke and spinal cord injury rehabilitation. Its products include IF 8000, an interferential and muscle stimulation device; IF 8100, a fixed program version of the IF8000; TruWave, a dual channel transcutaneous electrical nerve stimulation (TENS) device; E-Wave, a dual channel neuromuscular electrical stimulation device (NMES); and NM 900, an electromyography triggered electrical stimulation device. In addition, the company distributes Conti4000, an electrical stimulation device for incontinence treatment; ValuTENS, a dual channel TENS device; DCHT, a cervical traction device; LHT, a lumbar traction device; and electrodes that are re-usable for delivery of electrical current to the body. Its products are useful for patients suffering with impaired mobility from stroke and spinal cord injury, as well as for those suffering from acute and chronic pain. Zynex markets its products through commissioned and independent sales representatives, as well as directly to end users through advertisements and articles in relevant publications and on the Internet. The company was founded in 1998 and is headquartered in Littleton, Colorado. |
|
| Key Statistics |
| |
| | Pay | Exercised | Mr. Thomas Sandgaard , 50
Founder, Chairman, Chief Exec. Officer, Pres and Sec. |
$
319.00K | N/A | Mr. Fritz G. Allison , 49
Chief Financial Officer, Chief Accounting Officer and Treasurer |
N/A
| N/A |
|
|
|
Dollar amounts are as of
31-Dec-08
and compensation values are for the last fiscal
year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of
options exercised during the fiscal year.
| |
|
0.29% Nasdaq 0.00%
Profile
